Evotec SE and Bristol Myers Squibb Company will collaborate with researchers at four UK universities on identifying potential first-in-class therapeutics and the creation of spin-out companies, in the latest iteration of the German-based company’s BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) process for accelerating the translation of basic research into commercial products.
Evotec has refined its BRIDGE model since it was established in Oxford, UK, in 2016, and it now involves setting...